HLA-B and toxic epidermal necrolysis: Compared to the direct screening costs of mammography and Pap smear (i.e. excluding confirmatory diagnosis and all subsequent treatment costs if abnormalities were found [30], [31]), the cost of the current HLA-B*15∶02 screening was similar and up to five times higher in preventing death, reflecting the variability in the severity, and hence mortality, of SJS/TEN (Table 2).